Loading…
Employees: 1,645
Size Boryung (003850.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $531M, the 320th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩8,530 on 6 Nov 2026.
Performance Over six months the shares fell 14.2%, against -10.0% for the median peer and -24.5% for the South Korea market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 6.4% over the last twelve months (peer median +9.4%); the operating margin is 6.3% (peer median 10.0%).
Valuation It trades at 11.1× forward earnings against a peer median of 19.5× (2nd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.9 points above its cost of capital (5.1% WACC).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.09T | ₩1.02T | ₩1.02T | ₩860B | ₩760B |
| Revenue growth | — | 0% | +18% | +13% | — |
| Gross profit | n/a | ₩352B | ₩343B | ₩333B | ₩293B |
| EBITDA | n/a | ₩109B | ₩113B | ₩112B | ₩93.2B |
| Net income | ₩73.4B | ₩64.3B | ₩69.6B | ₩40.2B | ₩41.9B |
| Free cash flow | n/a | ₩112B | ₩67.7B | ₩27.2B | ₩7.54B |
| Capital expenditure | n/a | ₩29.1B | ₩20.0B | ₩23.3B | ₩123B |
| Total debt | n/a | ₩330B | ₩169B | ₩204B | ₩208B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 003850.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.7% | -10.0% | 8th highest of 21 |
| 6-month return | -14.2% | -10.0% | 10th lowest of 21 |
| Distance from 52-week high | -21.0% | -32.1% | 5th highest of 21 |
| Revenue growth (TTM) | +6.4% | +9.4% | 10th lowest of 20 |
| Operating margin | 6.3% | 10.0% | 8th lowest of 18 |
| Forward P/E | 11.1× | 19.5× | 2nd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -8.9% | 6.7% | 2nd least demanding of 8 |
| Growth delivered (Del g) | +12.6% | +9.1% | 2nd highest of 8 |
| Hurdle (Req g minus delivered) | -21.5 pp | -11.5 pp | 3rd least demanding of 8 |
| ROIC minus cost of capital | +0.9 pp | -3.1 pp | 8th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 11.1× | -8.9% | +12.6% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | n/a | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | n/a | 17.7% | +4.4% |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 14.9× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | n/a | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 21.6× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | n/a | -5.2% | +9.6% |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | n/a | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 9.3× | -12.5% | +11.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 19.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | n/a | -3.9% | +7.6% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | n/a | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 75.5× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | n/a | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | n/a | n/a | n/a |